Aura Biosciences, Inc. (NASDAQ:AURA – Get Free Report) shares shot up 12.7% during trading on Monday following a better than expected earnings announcement. The stock traded as high as $7.33 and last traded at $7.3920. Approximately 269,788 shares traded hands during mid-day trading, a decline of 52% from the average session volume of 567,656 shares. The stock had previously closed at $6.56.
The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.08.
Analyst Ratings Changes
Several brokerages have weighed in on AURA. HC Wainwright decreased their price objective on shares of Aura Biosciences from $24.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Wall Street Zen lowered shares of Aura Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aura Biosciences in a research report on Monday, October 12th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $17.50.
Read Our Latest Report on AURA
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. Frazier Life Sciences Management L.P. raised its position in shares of Aura Biosciences by 39.2% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 7,100,000 shares of the company’s stock worth $50,410,000 after purchasing an additional 2,000,000 shares during the period. Montanova Capital LLC boosted its position in Aura Biosciences by 64.8% during the 2nd quarter. Montanova Capital LLC now owns 7,206,217 shares of the company’s stock valued at $51,164,000 after purchasing an additional 2,833,333 shares during the period. ADAR1 Capital Management LLC acquired a new position in Aura Biosciences during the 2nd quarter valued at approximately $924,000. Nantahala Capital Management LLC acquired a new position in Aura Biosciences during the 2nd quarter valued at approximately $20,952,313. Finally, Jupiter Topco LLC bought a new position in Aura Biosciences during the 2nd quarter worth $17,788,000. 96.75% of the stock is currently owned by institutional investors.
Aura Biosciences Stock Performance
The stock has a 50 day moving average of $6.54 and a 200 day moving average of $6.72. The stock has a market capitalization of $766.59 million, a P/E ratio of -4.23 and a beta of 0.41.
About Aura Biosciences
Aura Biosciences, Inc (NASDAQ:AURA) is a clinical-stage biotechnology company developing targeted therapies for cancer. The company’s platform is designed to use tumor-targeting virus-like particles to selectively bind to cancer cells and deliver therapeutic payloads, with the goal of treating tumors while limiting damage to surrounding healthy tissue.
Aura’s lead product candidate is AU-011, also known as belzupacap sarotalocan, an investigational therapy being developed for primary choroidal melanoma, a form of eye cancer.
Featured Stories
- Five stocks we like better than Aura Biosciences
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
